A Phase 1 Study of [225Ac]-FPI-1434 Injection

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.

Conditions

Advanced Solid Tumours
Endometrial Cancer
Cervical Cancer
Ovarian Cancer
Breast Cancer
Triple Negative Breast Cancer (TNBC)
HER2-negative Breast Cancer
Head and Neck Squamous Cell Carcinoma (HNSCC)
Adrenocortical Carcinoma
Uveal Melanoma

Interventions

DRUG: [111In]-FPI-1547 Injection
DRUG: [225Ac]-FPI-1434 Injection multi-dose
BIOLOGICAL: FPI-1175 Infusion
DRUG: [225Ac]-FPI-1434 Injection single-dose

Sponsor

Fusion Pharmaceuticals Inc.